Early Wet AMD Detection: Impact on Vision Outcomes, Challenges to Detection, and a Solution

Macular Degeneration: A Prevalent Problem
How Do You Identify and Diagnose Dry AMD?
What Role Can Primary Eye Care Professionals Play in Monitoring and Diagnosing Wet AMD?
Why is monitoring intermediate AMD important?
What impact does early Wet AMD detection have on visual outcomes?
If the goal is early Wet AMD detection to help prevent vision loss, then how are we doing?
What are some of the potential reasons that make it challenging to detect Wet AMD early?
Should the Amsler Grid be the Standard of Care?
What impact does severe vision loss have on a patient’s quality of life?
What impact does severe vision loss have on a patient’s quality of life?

FDA Indication for Use

The ForeseeHome is intended for use in the detection and characterization of central and paracentral metamorphopsia (visual distortion) in patients with age-related macular degeneration, as an aid in monitoring progression of disease factors causing metamorphopsia including but not limited to choroidal neovascularization (CNV). It is intended to be used at home for patients with stable fixation.

The ForeseeHome AMD Monitoring Program is only available by physician order and is intended to be used as an addition to regular eye exams.

The technical component of the ForeseeHome AMD Monitoring Program is covered by Medicare, subject to its coverage requirements for the test, to assess patients with dry AMD who are at risk of developing wet AMD. Please refer to your local Medicare Administrative Contractor (MAC) for which the ordering physician resides concerning coverage availability for the physician professional services component of the test.